Research programme: NMDA receptor modulators - Aptinyx

Drug Profile

Research programme: NMDA receptor modulators - Aptinyx

Alternative Names: NMDA receptor modulators - Naurex; NRX-1050; NRX-1051; NRX-1059; NRX-105x; NRX-1060; NRX-2085; NRX-20xx; NYX 783

Latest Information Update: 22 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aptinyx; Naurex
  • Class Peptides; Small molecules
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain injuries; Epilepsy; Neuropathic pain
  • No development reported Alzheimer's disease; Autistic disorder; Major depressive disorder; Schizophrenia

Most Recent Events

  • 10 Nov 2016 Preclinical development is ongoing for neuropathic pain in USA
  • 10 Nov 2016 Apintnyx receives three SBIR grants from divisions of the National Institutes of Health for development of novel compounds for Neuropathic pain and age-related cognitive decline
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top